Skip to main
ORKA

ORKA Stock Forecast & Price Target

ORKA Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oruka Therapeutics is positioned to be a strong player in the biotech industry with a promising pipeline and solid financials, making it an attractive investment. Their ongoing collaborations and partnerships further strengthen their position in the market, and the positive interim results and potential for annual or quarterly dosing of their pipeline drugs bode well for the company's future success.

Bears say

Oruka Therapeutics is facing significant risks and potential challenges, including delays in clinical trial progress, potential failures in demonstrating efficacy of its therapies and delays in regulatory filings and approval. Additionally, intense competition in the I&I market and slower-than-projected market uptake pose potential concerns, possibly leading to long-term dilution risk. Despite a DCF-based valuation projecting a price of $120 per share, a negative outlook may be warranted given these factors.

ORKA has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oruka Therapeutics Inc (ORKA) Forecast

Analysts have given ORKA a Strong Buy based on their latest research and market trends.

According to 11 analysts, ORKA has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oruka Therapeutics Inc (ORKA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.